A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy and safety using an Environmental challenge chamber in male subjects with seasonal allergic rhinitis.

Registry ID

EUCTR2008-004092-22

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

GlaxSmithKline Research & Development Limited

Start date

2008-09-03

Completion date

2008-11-27

Last update

2026-08-16

Conditions

• Seasonal Allergic Rhinitis

Summary

To investigate the effect of single doses of oral GSK835726 on nasal symptoms of allergic rhinitis following 4 hrs in the allergen Challenge Chamber post-dose on day 1.

Locations

• , , Germany

Related clinical trials

• Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
• The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy
• Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis
• Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis
• A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
• Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis

View on source registry